Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 2:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 810 matching trials from the live ClinicalTrials.gov search.
Filters: "pulmonary hypertension" Condition: Hypertension Clear all
Completed Phase 3 Interventional Results available

Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial

NCT01224210
View directory record Official record
Conditions
Portopulmonary Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
6
States / cities
La Jolla, California • Jacksonville, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 12, 2026, 2:28 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Sedation With Dexmedetomidine During Cardiac Catheterization

NCT01072643
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Dexmedetomidine
Drug
Lead sponsor
Aruna Nathan
Other
Eligibility
8 Years to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 12, 2026, 2:28 AM EDT
Completed Phase 2 Interventional

Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension

NCT00352482
View directory record Official record
Conditions
Pulmonary Fibrosis, Hypertension, Pulmonary
Interventions
Sildenafil (50 mg)
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 12, 2026, 2:28 AM EDT
Recruiting Not applicable Interventional

Phenotyping Resting and Exertional Right Ventricular Dysfunction Among Patients With Chronic Obstructive Pulmonary Disease

NCT05896579
View directory record Official record
Conditions
COPD, Pulmonary Hypertension, Right Ventricular Dysfunction, Exercise, Exercise Training
Interventions
Exercise
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 12, 2026, 2:28 AM EDT
Terminated Phase 2Phase 3 Interventional

A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

NCT05036135
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
AV-101, Placebo
Drug
Lead sponsor
Aerovate Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 12, 2026, 2:28 AM EDT
Withdrawn Not applicable Interventional

Pilot Randomized Trial of Ambulatory Exercise in Pulmonary Hypertension

NCT04254289
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Usual Care, Home-based exercise program
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 12, 2026, 2:28 AM EDT
Terminated Not applicable Interventional

Arts & Health Education to Improve Health, Resilience, and Well-Being

NCT04154579
View directory record Official record
Conditions
Hypertension, Diabetes, Obesity, COPD, CHF, High Cholesterol, Asthma, Chronic Pain, Multiple Sclerosis, Depression, Anxiety, Heart Diseases, Stroke
Interventions
HeRe We Arts, HeRe We Ed
Behavioral
Lead sponsor
Lisa Gallagher
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Euclid, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Oct 12, 2026, 2:28 AM EDT
Recruiting No phase listed Observational

Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG

NCT07087613
View directory record Official record
Conditions
Hypertension, Pulmonary, Heart Failure With Reduced Ejection Fraction
Interventions
Eko CORE 500 Digital Stethoscope
Device
Lead sponsor
Eko Devices, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,850 participants
Timeline
2025 – 2027
U.S. locations
4
States / cities
O'Fallon, Illinois • Springfield, Illinois • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 12, 2026, 2:28 AM EDT
Completed No phase listed Observational

Linking Former Inmates to Primary Care

NCT01863290
View directory record Official record
Conditions
Hypertension, Substance Abuse, Asthma, Depression
Interventions
Primary care redesign
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
816 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Martinez, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 12, 2026, 2:28 AM EDT
Terminated Phase 2 Interventional Results available

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

NCT00467896
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Iloprost PD-6, Iloprost PD-15
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 85 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Phoenix, Arizona • La Jolla, California • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 12, 2026, 2:28 AM EDT
Completed Phase 1 Interventional Results available

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

NCT03950739
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Inhalation Powder
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 12, 2026, 2:28 AM EDT
Terminated Phase 3 Interventional Results available

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

NCT03657095
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Esuberaprost, Placebo
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 85 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 12, 2026, 2:28 AM EDT
Not listed No phase listed Observational

Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)

NCT01467791
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Hypertension
Interventions
Observation
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 12, 2026, 2:28 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Hormonal, Metabolic, and Signaling Interactions in PAH

NCT01884051
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 90 Years
Enrollment
1,899 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2032
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 12, 2026, 2:28 AM EDT
Completed Phase 3 Interventional

A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities

NCT00935077
View directory record Official record
Conditions
Hypertension, Asthma
Interventions
PPCM Asthma, 24 Month PPCM BP, 9 Month PPCM BP
Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
1,441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
28
States / cities
San Diego, California • Hartford, Connecticut • Gainesville, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Oct 12, 2026, 2:28 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

MECA Clinical Intervention ( MECA Health360x)

NCT04791618
View directory record Official record
Conditions
Cardiovascular Health, Self-management
Interventions
Health360x plus health coach, Health360x only (High tech)
Behavioral
Lead sponsor
Morehouse School of Medicine
Other
Eligibility
21 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 12, 2026, 2:28 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 12, 2026, 2:28 AM EDT
Completed Phase 2 Interventional

Aerobic Exercise in Patients With Pulmonary Hypertension

NCT00678821
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Aerobic exercise
Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
21 Years to 82 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 12, 2026, 2:28 AM EDT
Completed No phase listed Observational

Secondary Pulmonary Hypertension in Adults With Sickle Cell Anemia

NCT00011648
View directory record Official record
Conditions
Pulmonary Hypertension, Sickle Cell Anemia, Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 12, 2026, 2:28 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

NCT01392469
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib, Sildenafil, Bosentan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Tampa, Florida • Weston, Florida • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 12, 2026, 2:28 AM EDT
Completed No phase listed Observational

Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy

NCT00452283
View directory record Official record
Conditions
Glaucoma, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 12, 2026, 2:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

World Trade Center Adolescent Health Study

NCT02068183
View directory record Official record
Conditions
Asthma, Hypertension, Cardiovascular Risk Factor, Insulin Resistance, Stress Disorders, Post-Traumatic, Exposure to Toxic Dust
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
12 Years to 20 Years
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 12, 2026, 2:28 AM EDT
Completed No phase listed Observational

The Effects of Drug Candidate CS1 on Lung Structure and Function Utilizing FRI

NCT06907693
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
CT Pulmonary Angiography Scan
Diagnostic Test
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 12, 2026, 2:28 AM EDT
Withdrawn Not applicable Interventional

FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan

NCT02958358
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
CT imaging, functional PET imaging
Other
Lead sponsor
Robert Scott Harris, M.D.
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 12, 2026, 2:28 AM EDT